


### Subcommittee Myelodysplastic Syndrome

Chair: Marie Robin, Vice-Chair: Christof Scheid, CMML: Francesco Onida

#### Overview of registered MDS patients



#### Proposed studies

##### Therapy-related myeloid neoplasms

A large data quality initiative has just been finalized about patients who had a primary cancer before their MDS/AML main indication diagnosis of the stem cell transplantation. The 114 participating centers enriched the information in the EBMT registry substantially, which resulted in a proposal for four new studies:

- ❖ Outcome of patients transplanted after a primary diagnosis of cancer (n=520) – Marie Robin.
- ❖ Outcome of patients transplanted after breast cancer (n=593) – Mitja Nabergoj.
- ❖ Outcome of patients transplanted after lymphoma (n=960) – Livia Giannoni.
- ❖ Outcome of patients transplanted after plasma cell disorders (n=108) – Sarah Lawless.

Centers with eligible patients will in due course receive a data request.

#### Active survey

##### Pre-emptive hypomethylating agents for adverse risk MDS patients

Last month, a survey invitation has been sent out for a retrospective study of the CMWP. Here, we seek information on treatment protocol for adverse risk MDS patients with a TP53 mutation, regarding the use of hypomethylating drugs. The primary aim of this study is to compare the progression free survival of patients who were treated with pre-emptive hypomethylating agents post-transplant versus those who did not receive this treatment.

#### Poster Session

##### Tuesday March 26<sup>th</sup> 09:00–17:30, Areal

- B046 - Outcomes after Unrelated Cord Blood Transplantation (UCBT) for patients with Chronic Myeloid Leukemia (CML): a retrospective study from the CMWP – Hugues de Lavallade
- B341 - Does donor KIR-genotype impact outcome after unrelated hematopoietic stem cell transplantation for myelodysplastic syndromes or secondary acute myeloid leukemia? – Johannes Schetelig

#### Recently published articles

##### Optimized EBMT Transplant-Specific Risk Score in Myelodysplastic Syndromes after Allogeneic Stem-Cell Transplantation

Gageimann N, Eikema DJ, Stelljes M, Beelen D, de Wreede L, Mufti G, Knelange NS, Niederwieser D, Friis LS, Ehnninger G, Nagler A, Yakoub-Agha I, Meijer E, Ljungman P, Maertens J, Kanz L, Lopez-Corral L, Brecht A, Craddock C, Finke J, Cornelissen JJ, Bernasconi P, Chevallier P, Sierra J, Robin M & Kröger N. *Haematologica*. 2019 Jan 17. doi:10.3324/haematol.2018.200808 [Epub ahead of print].

##### Impact of Primary Disease on Outcome after Allogeneic Stem Cell Transplantation for Transformed Secondary Acute Leukemia

Kröger N, Eikema DJ, Koster L, Beelen D, de Wreede LC, Finke J, Könecke C, Niederwieser D, Bornhäuser M, Schönland S, Potter V, Wolschke C, Maertens J, Theobald M, Kobbe G, Itälä-Remes M, Wulf G, Kahls P, Forcade E, Greinix H, Masszi T, Yakoub-Agha I, Chalandon Y & Robin M. *British Journal of Haematology*, in press.

##### HLA-Mismatched Donors in Patients with Myelodysplastic Syndrome: An EBMT Registry Analysis

Robin M, Porcher R, Ruggeri A, Blaise D, Wolschke C, Koster L, Angelucci E, Stölzel F, Potter V, Yakoub-Agha I, Koc Y, Ciceri F, Finke J, Labussière-Wallet H, Cascon MJ, Verbeek M, Rambaldi A, Cornelissen JJ, Chevallier P, Radia R, Nagler A, Fegueux N, Gluckman E, de Witte T & Kröger N. *Biology of Blood and Marrow Transplantation*. 2019 Jan;25(1):114-120. doi:10.1016/j.bbmt.2018.08.026.

##### Late Treatment-related Mortality versus Competing Causes of Death after Allogeneic Transplantation for Myelodysplastic Syndromes and Secondary Acute Myeloid Leukemia

Schetelig J, de Wreede LC, van Gelder M, Koster L, Finke J, Niederwieser D, Beelen D, Mufti GJ, Platzbecker U, Ganser A, Heidenreich S, Maertens J, Socié G, Brecht A, Stelljes M, Kobbe G, Volin L, Nagler A, Vitek A, Luft T, Ljungman P, Yakoub-Agha I, Robin M & Kröger N. *Leukemia*. 2018 Dec 20. doi:10.1038/s41375-018-0302-y [Epub ahead of print].

##### Long-term Outcome After Allogeneic Hematopoietic Cell Transplantation For Myelofibrosis

Robin M, de Wreede LC, Wolschke C, Schetelig J, Eikema DJ, van Lint MT, Knelange NS, Beelen D, Brecht A, Niederwieser D, Vitek A, Bethge W, Arnold R, Finke J, Volin L, Yakoub-Agha I, Nagler A, Poiré X, Einsele H, Chevallier P, Holler E, Ljungman P, Robinson S, Radujkovic A, McLornan D, Chalandon Y & Kröger N. *Haematologica*. 2019 Feb. doi:10.3324/haematol.2018.205211 [Epub ahead of print].

##### Antilymphocyte Globulin for Matched Sibling Donor Transplantation in Patients with Myelofibrosis

Robin M, Chevret S, Koster L, Wolschke C, Yakoub-Agha I, Bourhis JH, Chevallier P, Cornelissen JJ, Reményi P, Maertens J, Poiré X, Craddock C, Socié G, Itälä-Remes M, Schouten HC, Marchand T, Passweg J, Blaise D, Damaj G, Ozkurt ZN, Zuckerman T, Cluzeau T, Labussière-Wallet H, Cammenga J, McLornan D, Chalandon Y & Kröger N. *Haematologica*. 2019 Jan. doi:10.3324/haematol.2018.201400 [Epub ahead of print].


##### Family Mismatched Allogeneic Stem Cell Transplantation for Myelofibrosis: Report from the Chronic Malignancies Working Party of European Society for Blood and Marrow Transplantation

Raj K, Eikema DJ, McLornan DP, Olavarria E, Blok HJ, Bregante S, Ciceri F, Passweg J, Schaap N, Carlson K, Zuckerman T, de Wreede LC, Volin L, Koc Y, Diez-Martin JL, Brossart P, Wolf D, Blaise D, Bartolomeo PD, Vitek A, Robin M, Yakoub-Agha I, Chalandon Y & Kröger N. *Biology of Blood and Marrow Transplantation*. 2018 Nov. doi:10.1016/j.bbmt.2018.10.017 [Epub ahead of print].

### Subcommittee Myeloproliferative Neoplasms

Chair: Donal McLornan, Vice-Chairs: Juan Carlos Hernández-Boluda & Tomasz Czerw

#### Overview of registered MPN patients



#### Proposed study

##### Impact of spleen size and splenectomy in MF

The decision about whether to perform a splenectomy before giving conditioning regimen in MF patients with splenomegaly who are ineligible, refractory or intolerant to Ruxolitinib is still a matter of debate. Within the CMWP, a retrospective study has been proposed to evaluate the effect of splenectomy and spleen size on outcome of allogeneic transplantation. A data request can be expected soon.

#### Call for patient identification


##### FGFR1-rearranged Myeloid/Lymphoid Neoplasm (MLN)

We are looking for centers that have treated MLN patients with a rearrangement of the FGFR1 gene. Because of the rarity of the disease, the EBMT registry contains only a few patients with this diagnosis. We are requesting centers to search for adult patients with FGFR1-rearranged MLN for a study that aims to analyze transplant outcome in this population. Please send the Unique Identification Code (UIC) to cmwpebmt@lumc.nl.

### Subcommittee Chronic Myeloid Leukaemia

Chair: Yves Chalandon

#### Overview of registered CML patients



#### Coming soon: DQI

##### Data Quality Initiative (DQI) for CML

To improve the data quality and availability of the registry, a request to participate in a DQI will be sent out in due time. The focus will be on TKI treatment and cytogenetics of patients transplanted for CML.

### Chronic Malignancies Working Party Session

#### Monday March 25<sup>th</sup> 09:00-10:30, Illusion 2

- 09:00–09:05 Introduction from the Chair of the CMWP - Ibrahim Yakoub-Agha, France
- 09:05–09:22 Who to transplant in the era of novel agents in 2019? - Nicolaus Kröger, Germany
- 09:22–09:39 Choice of conditioning and use of alternate donors - Kavita Raj, United Kingdom
- 09:39–09:56 JAK inhibitors pre- and post-allo SCT for myelofibrosis - Alessandro Rambaldi, Italy
- 09:56–10:13 Role of splenectomy pre- and post-allo SCT for MF - Marie Robin, France
- 10:13–10:28 Prevention and management of relapse in allo SCT for MF - Donal McLornan, United Kingdom
- 10:28–10:30 Concluding remarks - Ibrahim Yakoub-Agha, France

### Oral Session 2: Chronic leukaemia and other myeloproliferative disorders

#### Monday March 25<sup>th</sup> 16:00-17:30, Spektrum 1 + 2

- 16:00–16:11 OS2-1: Allogeneic stem cell transplantation for blast crisis CML in the era of tyrosine kinase inhibitors: a retrospective study by the EBMT Chronic Malignancies Working Party – Aleksandar Radujkovic
- 16:55–17:06 OS2-6: TKI discontinuation after allogeneic stem cell transplantation in patients with Chronic Myeloid Leukemia (CML): a retrospective study from the CMWP – Hugues de Lavallade